Literature DB >> 25959548

Valvular Regurgitation Using Portable Echocardiography in a Healthy Student Population: Implications for Rheumatic Heart Disease Screening.

Rachel H Webb1, Tom L Gentles2, John W Stirling2, Mildred Lee2, Clare O'Donnell2, Nigel J Wilson2.   

Abstract

BACKGROUND: There is increasing use of portable echocardiography as a screening test for rheumatic heart disease (RHD). The prevalence of valvular regurgitation in healthy populations as determined using portable echocardiography has not been well defined. Minimal echocardiographic criteria for RHD have recently been clarified, but the overlap of normal and abnormal valvular regurgitation warrants further study. The aim of this study was to determine the spectrum of echocardiographic findings using portable echocardiography in children from a population with low prevalence of RHD.
METHODS: Screening echocardiography was conducted in 396 healthy students aged 10 to 12 years using portable echocardiographic equipment. Echocardiograms were assessed according to 2012 World Heart Federation criteria for RHD. The prevalence of physiologic valvular regurgitation was compared with that found in previous studies of children using large-platform machines.
RESULTS: Physiologic mitral regurgitation (MR) was present in 14.9% of subjects (95% CI, 11.7%-18.7%) and pathologic MR in 1.3% (95% CI, 0.6%-2.9%). Two percent (95% CI, 1.0%-3.9%) had physiologic aortic regurgitation, and none had pathologic aortic valve regurgitation. Physiologic tricuspid regurgitation was present in 72.7% of subjects (95% CI, 68.1%-76.9%) and physiologic pulmonary regurgitation in 89.6% (95% CI, 85.7%-91.8%). After cardiology review, no cases of definite RHD were found, but 0.5% of patients (95% CI, 0.1%-1.8%) had pathologic MR meeting World Heart Federation criteria for borderline RHD. Two percent (95% CI, 1.4%-4.6%) of the cohort had minor forms of congenital heart disease.
CONCLUSIONS: The spectrum of physiologic cardiac valvular regurgitation in healthy children as determined using portable echocardiography is described and is within the range of previous studies using large-platform echocardiographic equipment. The finding of two children with pathologic-grade MR, likely representing the upper limit of physiologic regurgitation, has implications for echocardiographic screening for RHD in high-prevalence regions.
Copyright © 2015 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ARF; Echocardiography; Public health screening; RHD; Valvular regurgitation

Mesh:

Year:  2015        PMID: 25959548     DOI: 10.1016/j.echo.2015.03.012

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  11 in total

1.  Echocardiographic Screening of Rheumatic Heart Disease in American Samoa.

Authors:  Jennifer H Huang; Michael Favazza; Arthur Legg; Kathryn W Holmes; Laurie Armsby; Ipuniuesea Eliapo-Unutoa; Thomas Pilgrim; Erin J Madriago
Journal:  Pediatr Cardiol       Date:  2017-09-20       Impact factor: 1.655

2.  Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda.

Authors:  Brigette Gleason; Grace Mirembe; Judith Namuyonga; Emmy Okello; Peter Lwabi; Irene Lubega; Sulaiman Lubega; Victor Musiime; Cissy Kityo; Robert A Salata; Chris T Longenecker
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

3.  Inter-rater and intra-rater reliability and agreement of echocardiographic diagnosis of rheumatic heart disease using the World Heart Federation evidence-based criteria.

Authors:  Bo Remenyi; Jonathan Carapetis; John W Stirling; Beatrice Ferreira; Krishnan Kumar; John Lawrenson; Eloi Marijon; Mariana Mirabel; A O Mocumbi; Cleonice Mota; John Paar; Anita Saxena; Janet Scheel; Satu Viali; I B Vijayalakshmi; Gavin R Wheaton; Liesl Zuhlke; Karishma Sidhu; Eliazar Dimalapang; Thomas L Gentles; Nigel J Wilson
Journal:  Heart Asia       Date:  2019-06-24

4.  Novice Physician Ultrasound Evaluation of Pediatric Tricuspid Regurgitant Jet Velocity.

Authors:  Zachary W Binder; Sharon E O'Brien; Tehnaz P Boyle; Howard J Cabral; Sepehr Sekhavat; Joseph R Pare
Journal:  West J Emerg Med       Date:  2020-06-24

5.  Screening for rheumatic heart disease: quality and agreement of focused cardiac ultrasound by briefly trained health workers.

Authors:  Daniel Engelman; Joseph H Kado; Bo Reményi; Samantha M Colquhoun; Jonathan R Carapetis; Nigel J Wilson; Susan Donath; Andrew C Steer
Journal:  BMC Cardiovasc Disord       Date:  2016-02-01       Impact factor: 2.298

Review 6.  Screening for rheumatic heart disease: is a paradigm shift required?

Authors:  L D Hunter; M Monaghan; G Lloyd; A J K Pecoraro; A F Doubell; P G Herbst
Journal:  Echo Res Pract       Date:  2017-09-01

7.  Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.

Authors:  Rima Nabbout; Arun Mistry; Sameer Zuberi; Nathalie Villeneuve; Antonio Gil-Nagel; Rocio Sanchez-Carpintero; Ulrich Stephani; Linda Laux; Elaine Wirrell; Kelly Knupp; Catherine Chiron; Gail Farfel; Bradley S Galer; Glenn Morrison; Michael Lock; Anupam Agarwal; Stéphane Auvin
Journal:  JAMA Neurol       Date:  2020-03-01       Impact factor: 18.302

Review 8.  Imaging assessment of mitral and aortic regurgitation: current state of the art.

Authors:  Richard Paul Steeds; Saul G Myerson
Journal:  Heart       Date:  2020-08-17       Impact factor: 5.994

9.  Interscallop separations of the posterior mitral valve leaflet: a solution to the 'borderline RHD' conundrum?

Authors:  Luke David Hunter; Mark Monaghan; Guy Lloyd; Carl Lombard; Alfonso Jan Kemp Pecoraro; Anton Frans Doubell; Philipus George Herbst
Journal:  Open Heart       Date:  2020-11

10.  Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.

Authors:  Wyman W Lai; Bradley S Galer; Pierre C Wong; Gail Farfel; Milka Pringsheim; Martin G Keane; Anupam Agarwal
Journal:  Epilepsia       Date:  2020-08-18       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.